CN Patent

CN112321604A — 大环类jak2抑制剂及其应用

Assigned to East China University of Science and Technology · Expires 2021-02-05 · 5y expired

What this patent protects

本发明涉及一种大环类JAK2抑制剂及其应用。具体而言，本发明涉及下式I所示化合物及所述化合物在治疗JAK2介导的相关疾病以及制备治疗JAK2介导的相关疾病的药物中的用途。

USPTO Abstract

本发明涉及一种大环类JAK2抑制剂及其应用。具体而言，本发明涉及下式I所示化合物及所述化合物在治疗JAK2介导的相关疾病以及制备治疗JAK2介导的相关疾病的药物中的用途。

Drugs covered by this patent

Lorbrena (lorlatinib) · Pfizer

Patent Metadata

Patent number: CN112321604A
Jurisdiction: CN
Classification: —
Expires: 2021-02-05
Drug substance claim: No
Drug product claim: No
Assignee: East China University of Science and Technology
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.